---
title: "Nomura lowers the target price of AKESO to 112.73 yuan with a rating of \"Neutral\""
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/277868225.md"
description: "Nomura has lowered the target price for AKESO to RMB 112.73, maintaining a \"Neutral\" rating. It is expected that the company's revenue last year reached RMB 3.3 billion, in line with market expectations, mainly driven by drug sales in the second half of the year. The gross margin improved to 82.1%, operating expenses were flat, and net profit was RMB 38 million, below expectations. It is projected that revenue for the fiscal year 2026 will reach RMB 5.3 billion, with a gross margin of 84.5% and net profit of RMB 954 million, exceeding expectations. Revenue forecasts have been revised down by 2% and 5%, respectively"
datetime: "2026-03-05T02:20:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277868225.md)
  - [en](https://longbridge.com/en/news/277868225.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277868225.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/277868225.md) | [繁體中文](https://longbridge.com/zh-HK/news/277868225.md)


# Nomura lowers the target price of AKESO to 112.73 yuan with a rating of "Neutral"

Nomura published a research report, predicting that AKESO (09926.HK) will achieve revenue of 3.3 billion RMB last year, roughly in line with market expectations, primarily driven by drug sales of 1.8 billion RMB in the second half of the year. The firm expects the company's gross margin to improve to 82.1% in the second half of last year, compared to 79.4% in the first half; operating expenses are expected to reach 1.5 billion RMB, consistent with the first half; and net profit is expected to be 38 million RMB, below market expectations.

As for the fiscal year 2026, the firm expects the group's revenue to reach 5.3 billion RMB, in line with market expectations; gross margin is expected to be 84.5%; operating expenses are expected to reach 3.3 billion RMB; and net profit is expected to be 954 million RMB, higher than the market expectation of 605 million RMB.

The firm has lowered its revenue forecasts for AKESO for 2025 and 2026 by 2% and 5%, respectively, and has adjusted the target price from 120.64 RMB to 112.73 RMB, maintaining a "Neutral" rating

### Related Stocks

- [Minsheng Royal CSI Biotechnology Theme ETF (516930.CN)](https://longbridge.com/en/quote/516930.CN.md)
- [Bosera Hang Seng SCHK Innovative Drug Select ETF (520690.CN)](https://longbridge.com/en/quote/520690.CN.md)
- [Hwabao WP Hang Seng SCHK Innovative Drug Select ETF (520880.CN)](https://longbridge.com/en/quote/520880.CN.md)
- [AKESO (09926.HK)](https://longbridge.com/en/quote/09926.HK.md)
- [E Fund Hang Seng SCHK Innovative Drug ETF (159316.CN)](https://longbridge.com/en/quote/159316.CN.md)

## Related News & Research

- [CICC Remains a Buy on Akeso, Inc. (9926)](https://longbridge.com/en/news/281674709.md)
- [Akeso FY revenue RMB 3,056.3 million](https://longbridge.com/en/news/280664190.md)
- [Junshi Biosciences Chairman Completes RMB100 Million Shareholding Increase](https://longbridge.com/en/news/281231901.md)
- [Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst⢠(bumetanide nasal spray)](https://longbridge.com/en/news/281570860.md)
- [Wall Street sees multi-billion dollar debut for Lilly's obesity pill despite Novo lead](https://longbridge.com/en/news/281538820.md)